Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
155 studies found for:    "Clear cell renal cell carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: Nivolumab
2 Recruiting A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Conditions: ccRCC;   RCC;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Interventions: Drug: PART 1: PT2385 Tablets;   Drug: PART 2: PT2385 Tablets in combination with nivolumab;   Drug: PART 3: PT2385 Tablets in combination with cabozantinib
3 Recruiting Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: G-202
4 Completed Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Sunitinib
5 Active, not recruiting
Has Results
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Drug: Everolimus
6 Unknown  Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Conditions: Clear Cell Renal Cell Carcinoma;   Metastasis
Intervention: Drug: Sunitinib
7 Suspended SLM + Axitinib for Clear Cell RCC
Condition: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Interventions: Drug: Selenomethionine (SLM);   Drug: Axitinib
8 Terminated Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Hereditary Clear Cell Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: sorafenib tosylate;   Procedure: diffusion-weighted magnetic resonance imaging
9 Completed
Has Results
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: tandutinib;   Other: laboratory biomarker analysis
10 Not yet recruiting Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: X4P-001;   Drug: Nivolumab
11 Recruiting Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
12 Recruiting Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
Conditions: Clear Cell Renal Cell Carcinoma;   Melanoma;   Non-small Cell Lung Cancer
Interventions: Drug: CB-839;   Drug: Nivolumab
13 Recruiting Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Drug: Nivolumab;   Radiation: Nivolumab with concurrent Stereotactic Ablative Radiation Therapy
14 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
15 Completed AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
16 Completed
Has Results
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Imatinib
17 Completed Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Lu-177-DOTA-girentuximab
18 Terminated
Has Results
Vandetanib to Treat Advanced Kidney Cancer
Condition: Advanced Clear Cell Renal Carcinoma
Intervention: Drug: vandetanib
19 Recruiting Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Condition: Kidney Cancer
Interventions: Drug: Pazopanib;   Drug: Temsirolimus;   Behavioral: Quality of Life Assessment;   Drug: Benadryl
20 Completed
Has Results
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: 124-Iodine-cG250 (124I-cG250);   Procedure: CT

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years